CytoSorbents Corp. (CTSO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Electromed, Inc.

Apyx Medical Corp.

KORU Medical Systems, Inc.

Hyperfine, Inc.

DarioHealth Corp.

Citius Pharmaceuticals, Inc.

Accelerate Diagnostics, Inc.

Cutera, Inc.

CytoSorbents Corp.

Clearpoint Neuro, Inc.

Vicarious Surgical, Inc.

Why is CytoSorbents Corp. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -21.28

Negative results in Jun 26

PRE-TAX PROFIT(Q) At USD -4.08 MM has Fallen at -50.43%
NET PROFIT(Q) At USD -4.08 MM has Fallen at -56.2%
INTEREST(HY) At USD 1.73 MM has Grown at 41.26%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -69.18%, its profits have risen by 44.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -69.18% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CytoSorbents Corp. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

CytoSorbents Corp.

-69.18%

0.29

1862.96%

S&P 500

15.36%

1.17

13.09%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-1.20%

EBIT Growth (5y)

-6.21%

EBIT to Interest (avg)

-21.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.23

Sales to Capital Employed (avg)

1.34

Tax Ratio

9.65%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

30.79%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.13

EV to EBIT

-2.69

EV to EBITDA

-2.98

EV to Capital Employed

2.67

EV to Sales

1.31

PEG Ratio

Dividend Yield

ROCE (Latest)

-99.60%

ROE (Latest)

-114.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -9.14 MM

RAW MATERIAL COST(Y)

Fallen by -3.34% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -3,404.93 %

NET SALES(Q)

Highest at USD 9.63 MM

OPERATING PROFIT(Q)

Highest at USD -1.93 MM

OPERATING PROFIT MARGIN(Q)

Highest at -20.01 %

-21What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -4.08 MM has Fallen at -50.43%

NET PROFIT(Q)

At USD -4.08 MM has Fallen at -56.2%

INTEREST(HY)

At USD 1.73 MM has Grown at 41.26%

ROCE(HY)

Lowest at -336.19%

CASH AND EQV(HY)

Lowest at USD 9.23 MM

Here's what is working for CytoSorbents Corp.

Operating Cash Flow

Highest at USD -9.14 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 9.63 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -1.93 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -20.01 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Debt-Equity Ratio

Lowest at -3,404.93 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -3.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CytoSorbents Corp.

Pre-Tax Profit

At USD -4.08 MM has Fallen at -50.43%

over average net sales of the previous four periods of USD -2.71 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -4.08 MM has Fallen at -56.2%

over average net sales of the previous four periods of USD -2.61 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 1.73 MM has Grown at 41.26%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv

Lowest at USD 9.23 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents